Qualigen (QGEN), formerly Ritter Pharmaceuticals, develops novel therapeutic products that includes gut microbiome modulation for gastrointestinal diseases, treatment for lactose intolerance (RP-G28), and other variety of conditions including immuno-oncology, metabolic, and liver disease.
In January Ritter Pharmaceuticals announced a reverse merger agreement in which Ritter will change its name to Qualigen, Inc., or a similar name selected by Qualigen. The purpose of this merger is to focus on development of Qualigen’s nanotechnology therapies for the treatment of cancer and infectious diseases.
Qualigen will also operate it’s profitable diagnostics business under a separate Contingent Value Right (CVR) agreement, a CVR holder representative will continue to seek opportunities to monetize Ritter Pharmaceuticals’ RP-G28 asset with financial support from Qualigen for a defined period, with the net proceeds of any monetization to be distributed to Ritter Pharmaceuticals’ pre-merger stockholders.
In conjunction with the merger transaction, Qualigen has arranged the securing of additional capital from an institutional investor (the “Pre-Closing Financing”) to support funding of its operations and expansion of its clinical development programs.
What Qualigen is doing
Qualigen is actively monitoring the COVID-19 situation, and we are working hard to keep labs and clinics supplied with the FastPacks they need to continue patient testing. Our team continues to manufacture and ship product at full capacity. We will inform you if the situation changes. Thank you for trusting Qualigen to provide your lab testing needs.
Qualigen is a biotechnology company focused on the development and commercialization of novel therapeutic products for the treatment of cancer and infectious diseases, as well as expansion of its flagship FastPack® diagnostic platform.
The FastPack® line of FDA-cleared and CE-Marked products has been used successfully in diagnostics since 2002. Our therapeutics pipeline includes cancer drug compounds such as AS1411, AS1411-GNP and RAS-F, as well as STARS, a DNA/RNA-based treatment device.
By combining our demonstrated ability to quickly develop and commercialize innovative medical products with the advanced capabilities of leading cancer research centers, such as the University of Louisville, we are committed to providing exciting new therapeutic technologies to physicians and patients.
Qualigen’s technilogical advances such as AS1411 a cancer drug, uses a specialized segment of DNA, known as an aptamer, to target and destroy tumor cells, without the serious side effects associated with other cancer therapies.
Our AS1411-GNP cancer drug combines this DNA aptamer with gold nanoparticle technology to increase its potency and broaden the potential applications to include combination therapy with radiation and tumor imaging.
The STARS device will use aptamer technology to cleanse a patient’s blood of circulating tumor cells, checkpoints and inflammation factors. STARS can also be used for infectious disease treatment, where it can capture and remove viruses.
RAS-F is a small-molecule drug designed to inhibit a genetic mutation that can turn a normal cell into a tumor cell.
The company’s flagship product line, FastPack®, combines magnetic particle immunochemistry with innovative disposable packaging technology to provide real-time diagnostic information for cancers and other serious medical conditions.
